MannKind Corporation (MNKD)
| Market Cap | 1.37B |
| Revenue (ttm) | 224.60M |
| Net Income (ttm) | 8.49M |
| Shares Out | 272.32M |
| EPS (ttm) | 0.04 |
| PE Ratio | 125.75 |
| Forward PE | 40.09 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,782,375 |
| Open | 5.06 |
| Previous Close | 5.09 |
| Day's Range | 4.95 - 5.08 |
| 52-Week Range | 3.17 - 5.75 |
| Beta | 1.27 |
| Analysts | Strong Buy |
| Price Target | 8.00 (+59.05%) |
| Earnings Date | Aug 5, 2024 |
About MNKD
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertensio... [Read more]
Financial Performance
In 2023, MannKind's revenue was $198.96 million, an increase of 99.42% compared to the previous year's $99.77 million. Losses were -$11.94 million, -86.34% less than in 2022.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for MNKD stock is "Strong Buy." The 12-month stock price forecast is $8.0, which is an increase of 59.05% from the latest price.
News
INHALE-3 Study Reveals Positive Readout in Head-to-Head Comparison of Inhaled Insulin vs. Usual Care in T1D; New Data Presented at American Diabetes Association's 84th Scientific Sessions
Study proves inhaled insulin is as effective as usual care (primarily automated insulin delivery pumps or multiple daily injections) for adults living with T1D meeting the primary endpoint Patients ut...
Inhale-3 Study Results to be Presented During a 90-Minute Symposium on Saturday, June 22 at the American Diabetes Association's 84th Scientific Sessions
INHALE-3 STUDY RESULTS TO BE PRESENTED DURING A 90-MINUTE SYMPOSIUM ON SATURDAY, JUNE 22 AT THE AMERICAN DIABETES ASSOCIATION'S 84TH SCIENTIFIC SESSIONS
MannKind to Establish Boston-Area Research & Development Foothold and Expand Portfolio of Dry Powder Inhalation Technology in Transaction With Pulmatrix
MANNKIND TO ESTABLISH BOSTON-AREA RESEARCH & DEVELOPMENT FOOTHOLD AND EXPAND PORTFOLIO OF DRY POWDER INHALATION TECHNOLOGY IN TRANSACTION WITH PULMATRIX
Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation
Cross license involves Pulmatrix iSPERSE™ technology and MannKind's Cricket® inhalation device. Pulmatrix transferring leased building, all leasehold improvements, laboratory equipment and other relat...
MannKind Corporation Reports 2024 First Quarter Financial Results: Provides Clinical Development Update
1Q 2024 Total revenues of $66M; +63% vs. 1Q 2023 1Q 2024 Net income of $11M; Non-GAAP net income of $15M $304M of cash and cash equivalents and investments at March 31, 2024 In early April, repaid Mid...
MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
DANBURY, Conn. and WESTLAKE VILLAGE, Calif.
MannKind Corporation to Hold 2024 First Quarter Financial Results Conference Call on May 8, 2024
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2024 first quarter financial results and its management will host a c...
MannKind to Proceed With Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases
First-in-human study to evaluate safety, tolerability and pharmacokinetics (PK) in healthy volunteers Enrollment of first study participant anticipated in June 2024 DANBURY, Conn. and WESTLAKE VILLAGE...
MannKind Announces IND Clearance From U.S. FDA to Start Phase 3 Study of Clofazimine Inhalation Suspension for Nontuberculous Mycobacterial (NTM) Lung Disease
DANBURY, Conn. and WESTLAKE VILLAGE, Calif.
MannKind Repays Certain Debt Obligations
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic ...
MannKind Announces CFO Transition
Steven B. Binder announces planned retirement and is appointed Executive Vice President, Special Projects, effective April 22, 2024, through December 31, 2024 Christopher Prentiss appointed Chief Fina...
INHALE-3 Study's Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections (MDI) and Insulin Pumps
Post-meal hyperglycemia was significantly reduced by 20% with inhaled insulin compared with rapid-acting insulin delivered through MDI or insulin pumps Subjects utilizing inhaled insulin experienced a...
MannKind Announces New Clinical Data From Inhale-3 Study to be Presented by Dr. Irl B. Hirsch at ATTD on March 8
Dr. Hirsch to present meal challenge results when switching from multiple daily injections (MDI) or insulin pumps to inhaled insulin (Afrezza® (insulin human) Inhalation Powder) Dr. Hirsch to present ...
MannKind Corporation Announces Participation at Upcoming Conferences
WESTLAKE VILLAGE, Calif. and DANBURY, Conn., March 04, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic p...
MannKind Corporation Reports 2023 Fourth Quarter and Full Year Financial Results: Provides Clinical Development Update
2023 Total revenues of $199M; +99% vs. 2022 4Q 2023 Total revenues of $58M; +62% vs.
MannKind Corporation to Hold 2023 Fourth Quarter and Full Year Financial Results Conference Call on February 27, 2024
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2023 fourth quarter and full year financial results and its manageme...
MannKind Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza®
Reached enrollment goal of 305 patients living with Type 1 or Type 2 diabetes Primary endpoint analysis expected in 4Q 2024 Data dissemination and FDA submission expected in 2025 DANBURY, Conn. and WE...
MannKind in royalty agreement with Sagard Healthcare for Tyvaso DPI
MannKind Corp. MNKD, -1.62% said Tuesday it has entered a royalty agreement with Sagard Healthcare under which the latter will receive 1% of royalty sales of Tyvaso DPI inhalation powder for up to $20...
MannKind and Sagard Healthcare Enter Into Royalty Purchase Agreement for Up to $200 Million
WESTLAKE VILLAGE, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced that on December 27, 2023 it sold a 1% royalty in net sales of Tyvaso DPI® (treprostinil) inha...
MannKind Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Dec. 28, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) a company focused on the development and commercialization of inhaled therapeutic pro...
MannKind Corporation Reports 2023 Third Quarter Financial Results
Conference Call to Begin Today at 5:00 p.m. (ET) 3Q 2023 Total revenues of $51M; +56% vs.
MannKind Announces Completion of Enrollment in U.S. Phase 4 Inhale-3 Clinical Trial in Patients Living With Type 1 Diabetes
Rapidly enrolled 141 patients in less than four months Large study will compare A1c from baseline to 17 weeks for adults when switching from injectable insulin or pumps to inhaled insulin (Afrezza ® (...
MannKind Corporation to Hold 2023 Third Quarter Financial Results Conference Call on November 7, 2023
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2023 third quarter financial results and year to date financial resu...
MannKind Expands Patent Portfolio With New Clofazimine Formulation Patent
DANBURY, Conn., Oct. 30, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patien...
MannKind Corporation Reports 2023 Second Quarter Financial Results
Conference Call to Begin Today at 5:00 p.m. (ET) 2Q 2023 Total revenues of $49M; +157% vs.